Cargando…
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
BACKGROUND: Patient-reported outcomes (PROs) are increasingly relevant endpoints in clinical trials, contributing to our understanding of risk–benefit profiles, in addition to efficacy and safety data. We investigated the impact of entrectinib on patient-reported symptoms, functioning, and health-re...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100628/ https://www.ncbi.nlm.nih.gov/pubmed/33930659 http://dx.doi.org/10.1016/j.esmoop.2021.100113 |
_version_ | 1783688827864350720 |
---|---|
author | Paz-Ares, L. Barlesi, F. Siena, S. Ahn, M.-J. Drilon, A. Conley, A. Rolfo, C. Wolf, J. Seto, T. Doebele, R. Kapre, A. Chen, D. McCallum, S. Osborne, S. Demetri, G. |
author_facet | Paz-Ares, L. Barlesi, F. Siena, S. Ahn, M.-J. Drilon, A. Conley, A. Rolfo, C. Wolf, J. Seto, T. Doebele, R. Kapre, A. Chen, D. McCallum, S. Osborne, S. Demetri, G. |
author_sort | Paz-Ares, L. |
collection | PubMed |
description | BACKGROUND: Patient-reported outcomes (PROs) are increasingly relevant endpoints in clinical trials, contributing to our understanding of risk–benefit profiles, in addition to efficacy and safety data. We investigated the impact of entrectinib on patient-reported symptoms, functioning, and health-related quality of life. PATIENTS AND METHODS: STARTRK-2 is a phase II basket study in patients with locally advanced/metastatic neurotrophic receptor tyrosine kinase 1/2/3 (NTRK1/2/3) and ROS proto-oncogene 1 (ROS1) fusion-positive solid tumours. PROs (prespecified secondary endpoint) were evaluated using the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (QLQ-C30), lung cancer module (QLQ-LC13), and colorectal cancer module (QLQ-CR29), and the EuroQoL 5-Dimension 3-Level instruments, completed before cycle 1 day 1 and each subsequent 4-week cycle of entrectinib dosing, and the end of treatment. Adverse events and treatment-related symptoms were assessed in the safety analysis (SA)-PRO population. Tumour-related symptoms, functioning, and global health status were assessed in the efficacy analysis (EA)-PRO population. Data cut-offs: 31 October 2018 NTRK cohort; 01 May 2019 ROS1 cohort. RESULTS: SA-PRO populations comprised patients with NTRK fusion-positive solid tumours (N = 88) or ROS1 fusion-positive non-small-cell lung cancer (N = 180) who received one or more doses of entrectinib, completed PRO questionnaires on cycle 1 day 1 and answered one or more questions on-study. EA-PRO populations (N = 71) and (N = 145), respectively, comprised SA-PRO patients with measurable baseline disease. Moderate-to-high baseline global health status scores were maintained in EA-PRO populations during treatment. Role and physical functioning scores were moderate-to-high at baseline, with trends towards clinical improvement during treatment. Both cohorts reported low-to-moderate symptom burden at baseline, which was maintained or trended towards clinically meaningful improvement. Symptoms commonly associated with cancer treatment (e.g. nausea, fatigue) remained stable or improved during treatment. All SA-PRO patients experienced one or more adverse events, most frequently constipation or diarrhoea. CONCLUSIONS: PRO findings were consistent with the favourable safety profile of entrectinib, and further reinforce the positive benefit–risk profile of this treatment, indicating minimal overall treatment burden. |
format | Online Article Text |
id | pubmed-8100628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81006282021-05-14 Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours Paz-Ares, L. Barlesi, F. Siena, S. Ahn, M.-J. Drilon, A. Conley, A. Rolfo, C. Wolf, J. Seto, T. Doebele, R. Kapre, A. Chen, D. McCallum, S. Osborne, S. Demetri, G. ESMO Open Original Research BACKGROUND: Patient-reported outcomes (PROs) are increasingly relevant endpoints in clinical trials, contributing to our understanding of risk–benefit profiles, in addition to efficacy and safety data. We investigated the impact of entrectinib on patient-reported symptoms, functioning, and health-related quality of life. PATIENTS AND METHODS: STARTRK-2 is a phase II basket study in patients with locally advanced/metastatic neurotrophic receptor tyrosine kinase 1/2/3 (NTRK1/2/3) and ROS proto-oncogene 1 (ROS1) fusion-positive solid tumours. PROs (prespecified secondary endpoint) were evaluated using the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (QLQ-C30), lung cancer module (QLQ-LC13), and colorectal cancer module (QLQ-CR29), and the EuroQoL 5-Dimension 3-Level instruments, completed before cycle 1 day 1 and each subsequent 4-week cycle of entrectinib dosing, and the end of treatment. Adverse events and treatment-related symptoms were assessed in the safety analysis (SA)-PRO population. Tumour-related symptoms, functioning, and global health status were assessed in the efficacy analysis (EA)-PRO population. Data cut-offs: 31 October 2018 NTRK cohort; 01 May 2019 ROS1 cohort. RESULTS: SA-PRO populations comprised patients with NTRK fusion-positive solid tumours (N = 88) or ROS1 fusion-positive non-small-cell lung cancer (N = 180) who received one or more doses of entrectinib, completed PRO questionnaires on cycle 1 day 1 and answered one or more questions on-study. EA-PRO populations (N = 71) and (N = 145), respectively, comprised SA-PRO patients with measurable baseline disease. Moderate-to-high baseline global health status scores were maintained in EA-PRO populations during treatment. Role and physical functioning scores were moderate-to-high at baseline, with trends towards clinical improvement during treatment. Both cohorts reported low-to-moderate symptom burden at baseline, which was maintained or trended towards clinically meaningful improvement. Symptoms commonly associated with cancer treatment (e.g. nausea, fatigue) remained stable or improved during treatment. All SA-PRO patients experienced one or more adverse events, most frequently constipation or diarrhoea. CONCLUSIONS: PRO findings were consistent with the favourable safety profile of entrectinib, and further reinforce the positive benefit–risk profile of this treatment, indicating minimal overall treatment burden. Elsevier 2021-04-27 /pmc/articles/PMC8100628/ /pubmed/33930659 http://dx.doi.org/10.1016/j.esmoop.2021.100113 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Research Paz-Ares, L. Barlesi, F. Siena, S. Ahn, M.-J. Drilon, A. Conley, A. Rolfo, C. Wolf, J. Seto, T. Doebele, R. Kapre, A. Chen, D. McCallum, S. Osborne, S. Demetri, G. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours |
title | Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours |
title_full | Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours |
title_fullStr | Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours |
title_full_unstemmed | Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours |
title_short | Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours |
title_sort | patient-reported outcomes from startrk-2: a global phase ii basket study of entrectinib for ros1 fusion-positive non-small-cell lung cancer and ntrk fusion-positive solid tumours |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100628/ https://www.ncbi.nlm.nih.gov/pubmed/33930659 http://dx.doi.org/10.1016/j.esmoop.2021.100113 |
work_keys_str_mv | AT pazaresl patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT barlesif patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT sienas patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT ahnmj patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT drilona patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT conleya patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT rolfoc patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT wolfj patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT setot patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT doebeler patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT kaprea patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT chend patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT mccallums patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT osbornes patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours AT demetrig patientreportedoutcomesfromstartrk2aglobalphaseiibasketstudyofentrectinibforros1fusionpositivenonsmallcelllungcancerandntrkfusionpositivesolidtumours |